Antibodies Targeting Human Endothelin-1 Receptors Reveal Different Conformational States in Cancer Cells
Open Access
- 6 May 2018
- journal article
- research article
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 67 (Suppl 1) , S257-S264
Abstract
The endothelin axis (endothelins and their receptors) is strongly involved in physiological and pathological processes. ET-1 plays a crucial role in particular in tumor diseases. Endothelin-1 receptors (ETA and ETB) are deregulated and overexpressed in several tumors such as melanoma and glioma. We studied the binding of 24 monoclonal antibodies directed against human ETB receptors (hETB) to different melanoma cell lines. Few of these mAbs bound to all the melanoma cell lines. One of them, rendomab B49, bound to ETB receptors expressed at the surface of human glioma stem cells. More recently, we produced new antibodies directed against human ETA receptor (hETA). Several antibodies have been isolated and have been screened on different tumoral cells lines. As for the mAbs directed against the hETB receptor only some of new antibodies directed against ETA receptor are capable to bind the human tumoral cell lines. Rendomab A63 directed against hETA is one of them. We report the specificity and binding properties of these mAbs and consider their potential use in diagnosis by an in vivo imaging approach.Keywords
This publication has 13 references indexed in Scilit:
- EndothelinPharmacological Reviews, 2016
- Notch1 Stimulation Induces a Vascularization Switch With Pericyte-Like Cell Differentiation of Glioblastoma Stem CellsStem Cells, 2014
- Endothelin 1 in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2013
- Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptormAbs, 2013
- Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug DiscoveryPharmacological Reviews, 2010
- Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.Canadian Journal of Physiology and Pharmacology, 2008
- Expression of Endothelin-1 and Endothelin Receptors in Cultured Human Glioblastoma CellsJournal of Cardiovascular Pharmacology, 2000
- Pharmacology of A-216546: a highly selective antagonist for endothelin ETA receptorEuropean Journal of Pharmacology, 1999
- Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707Neurosurgery, 1998
- Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistNature, 1993